Clinical Scenario
A 68-year-old male with poorly controlled type 2 diabetes and peripheral vascular disease is admitted to the ICU following emergency debridement of a necrotizing soft tissue infection involving his left lower limb. He presents with septic shock: hypotension requiring norepinephrine, high-grade fever, and altered mental status. Blood cultures grow Staphylococcus aureus, and broad-spectrum antibiotics including vancomycin are initiated.
Over the next 24 hours, the patient develops oliguric acute kidney injury, classified as KDIGO Stage III, with rising creatinine and fluid overload which eventually lead to requirement of invasive mechanical ventilation. Renal replacement therapy is initiated using Coupled Plasma Filtration Adsorption (CPFA) to address both renal dysfunction and the overwhelming inflammatory response (see Figure 1).
Figure 1. Coupled Plasma Filtration Adsorption (courtesy: https://mozarcmedical.com)
Despite standard vancomycin dosing (15 mg/kg IV q12h), his trough levels remain persistently subtherapeutic at 7 Β΅g/mL (target: 15β20 Β΅g/mL). Repeat cultures remain positive, and clinical signs of infection persist.
Wrong Answer: A. Vancomycin is not metabolized hepatically; systemic inflammation may alter distribution but not metabolism.
Wrong Answer: B. CPFA does not restore renal clearance; it replaces it. Hemodynamic stabilization does not increase vancomycin clearance.
Right Answer: C. Correct β CPFA removes vancomycin via adsorption to the resin cartridge and convective filtration, leading to subtherapeutic levels. In CPFA, antibiotics like vancomycin can be removed from the bloodstream via two concurrent mechanisms: β Adsorption onto the resin cartridge β Filtration through the extracorporeal circuit These processes can significantly lower plasma concentrations, causing trough levels to remain subtherapeutic despite standard dosing. Explaination: Coupled Plasma Filtration Adsorption (CPFA) is a complex extracorporeal blood purification technique designed to remove inflammatory mediators in critically ill patients, especially those with septic shock. A patient with septic shock and KDIGO Stage III AKI may be started on CPFA to: β Control overwhelming inflammation β Remove uremic toxins and manage fluid overload β Support organ recovery In this setup, CPFA serves as both extracorporeal immunotherapy and renal replacement therapy. Now coming to which one is the likely mechanism explaining subtherapeutic plasma levels of vancomycin in given case.
Clinical Pearls
Strategies to Address Underdosing 1. Therapeutic Drug Monitoring (TDM) β Regularly measure trough and peak levels, especially for vancomycin and aminoglycosides. β Adjust dosing based on CPFA clearance and patient pharmacokinetics. 2. Dose Adjustment β Increase dose or frequency (e.g., vancomycin q8h instead of q12h). β Consider continuous infusion for time-dependent antibiotics like Ξ²-lactams. 3. Timing Coordination β Administer antibiotics during CPFA downtime or post-session to minimize loss. 4. Alternative Agents β Use drugs with higher protein binding or larger molecular size (e.g., daptomycin instead of linezolid). 5. Multidisciplinary Review β Involve pharmacists, nephrologists, and intensivists to optimize antimicrobial therapy.
Wrong Answer: D. Capillary leak may increase volume of distribution, but it doesn't fully explain persistent low troughs during CPFA.
